Cargando…

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

BACKGROUND AND AIMS: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltr...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbedewy, Tamer A, Elsebaey, Mohamed A, Elshweikh, Samah A, Elashry, Heba, Abd-Elsalam, Sherief
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375108/
https://www.ncbi.nlm.nih.gov/pubmed/30804674
http://dx.doi.org/10.2147/TCRM.S186106
_version_ 1783395307425366016
author Elbedewy, Tamer A
Elsebaey, Mohamed A
Elshweikh, Samah A
Elashry, Heba
Abd-Elsalam, Sherief
author_facet Elbedewy, Tamer A
Elsebaey, Mohamed A
Elshweikh, Samah A
Elashry, Heba
Abd-Elsalam, Sherief
author_sort Elbedewy, Tamer A
collection PubMed
description BACKGROUND AND AIMS: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. PATIENTS AND METHODS: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×10(9)/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×10(9)/L) required to initiate antiviral therapy. RESULTS: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. CONCLUSION: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy.
format Online
Article
Text
id pubmed-6375108
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63751082019-02-25 Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia Elbedewy, Tamer A Elsebaey, Mohamed A Elshweikh, Samah A Elashry, Heba Abd-Elsalam, Sherief Ther Clin Risk Manag Original Research BACKGROUND AND AIMS: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. PATIENTS AND METHODS: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×10(9)/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×10(9)/L) required to initiate antiviral therapy. RESULTS: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. CONCLUSION: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy. Dove Medical Press 2019-02-11 /pmc/articles/PMC6375108/ /pubmed/30804674 http://dx.doi.org/10.2147/TCRM.S186106 Text en © 2019 Elbedewy et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Elbedewy, Tamer A
Elsebaey, Mohamed A
Elshweikh, Samah A
Elashry, Heba
Abd-Elsalam, Sherief
Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_full Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_fullStr Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_full_unstemmed Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_short Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_sort predictors for eltrombopag response in patients with hepatitis c virus-associated thrombocytopenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375108/
https://www.ncbi.nlm.nih.gov/pubmed/30804674
http://dx.doi.org/10.2147/TCRM.S186106
work_keys_str_mv AT elbedewytamera predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elsebaeymohameda predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elshweikhsamaha predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elashryheba predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT abdelsalamsherief predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia